Search

The article presents a study on persistent abnormalities in peripheral blood dendritic cells and monocytes from human immunodeficiency virus (HIV)-1-positive patients after one year of antiretroviral therapy (ART) in the U.S. The subjects were tested before therapy and after a number of weeks after starting ART. The results of the study show an incomplete T-cell immune reconstitution in chronically infected patients who had undetectable plasma viremia while taking ART for 1 year.

The article examines the international students program at the National War College of National Defense University in the U.S. International student participation in the university includes the international military and civilian personnel. International students are able to advance their studies and complete them. Also, long-lasting ties of friendship are formed between the U.S. and international students.

Despite the large amounts of resources destined to developing filtering algorithms of LiDAR point clouds in order to obtain a Digital Terrain Model (DTM), the task remains a challenge. As a society advancing towards the democratization of information and collaborative processes, the researchers should not only focus on improving the efficacy of filters, but should also consider the users' needs with a view toward improving the usability and accessibility of the filters in order to develop tools that will provide solutions to the challenges facing this field of study. In this work, we describe the Hybrid Overlap Filter (HyOF), a new filtering algorithm implemented in the free R software environment. The flow diagram of HyOF differs in the following ways from that of other filters developed to date: (1) the algorithm is formed by a combination of sequentially operating functions (i.e., the output of the first function provides the input of the second), which are capable of functioning independently and thus enabling integration of these functions with other filtering algorithms; (2) the variable penetrability is defined and used, along with slope and elevation, to identify ground points; (3) prior to selection of the seed points, the original point cloud is processed with the aim of removing points corresponding to buildings; and (4) a new method based on a moving window, with longitudinal overlap between windows and transverse overlap between passes, is used to select the seed points. Our hybrid filtering method is tested using 15 reference samples acquired by the International Society of Photogrammetry and Remote Sensing (ISPRS) and is evaluated in comparison with 33 existing filtering algorithms. The results show that our hybrid filtering method produces an average total error of 3.34% and an average Kappa coefficient of 92.62%. The proposed algorithm is one of the most accurate filters that has been tested with the ISPRS reference samples. [ABSTRACT FROM AUTHOR]

Background: A preliminary exploratory study shows solid agreement between the results of case reports and clinical study meta-analyses in mucopolysaccharidosis Type I (MPS-I) adult patients. The aim of the present study is to confirm previous results in another patient population, suffering from mucopolysaccharidosis Type II (MPS-II).Methods: A systematic review and meta-analysis of case reports published by April 2018 was conducted for MPS-II patients treated with enzyme replacement therapy (ERT). The study is reported in accordance with PRISMA and MOOSE guidelines (PROSPERO database code CRD42018093408). The assessed population and outcomes were the same as previously analyzed in a meta-analysis of MPS-II clinical studies. The primary endpoint was the percent of clinical cases showing improvement in efficacy outcome, or no harm in safety outcome after ERT initiation. A restrictive procedure to aggregate case reports, by selecting standardized and well-defined outcomes, was proposed. Different sensitivity analyses were able to evaluate the robustness of results.Results: Every outcome classified as "acceptable evidence group" in our case report meta-analysis had been graded as "moderate strength of evidence" in the aforementioned meta-analysis of clinical studies. Sensitivity, specificity, and positive-negative predictive values for results of both meta-analyses reached 100%, and were deemed equivalent.Conclusions: Aggregating case reports quantitatively, rather than analyzing them qualitatively, may improve conclusions in rare diseases and personalized medicine. Additionally, we propose some methods to evaluate publication bias and heterogeneity of the included studies in a meta-analysis of case reports. [ABSTRACT FROM AUTHOR]

• The optimal management of severe COVID-19 represents an unmet clinical need. • Programmed cell death-1/interleukin-6 receptor blockade might restore immunocompetence and interrupt hyperinflammation. • COPERNICO assessed pembrolizumab plus tocilizumab and standard of care (SOC) compared with SOC in high-risk patients with COVID-19. • The addition of pembrolizumab plus tocilizumab to SOC reduced the hospitalization period. • The addition of pembrolizumab plus tocilizumab to SOC reduced the rate of discharge without sequelae. Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating anti-programmed cell death-1 antibody) plus tocilizumab (TCZ; anti- interleukin 6 receptor antibody) might interrupt the hyperinflammation and restore cellular immunocompetence. We assessed the efficacy and safety of P + TCZ + standard of care (SOC) in high-risk, hospitalized patients with COVID-19 pneumonia without mechanical ventilation. Randomized, controlled, open-label, phase II trial in patients with severe SARS-CoV-2 infection to assess the hospitalization period to discharge. A total of 12 patients were randomized (P + TCZ + SOC, n = 7; SOC, n = 5). Nine (75%) were males, with a median age of 68 (41-79) years. The median time to discharge for P + TCZ + SOC and SOC was 10 and 47.5 days (P = 0.03), with zero (n = 1 patient had P-related grade 5 myositis) and two COVID-19-related deaths, respectively. The addition of P and TCZ to SOC reduced the hospitalization period, with higher and faster discharges without sequelae than SOC alone. [ABSTRACT FROM AUTHOR]

Background: Nutritional problems, anaemia and infectious diseases are themain causes of morbidity andmortality in children and adolescents in tropical and subtropical areas. The main objective of this study was to determine the nutritional status in children from low-income countries who migrated to Spain and the value of the usual biochemistry markers of nutrition in these children, as well as to evaluate the nutritional status associated with imported infectious diseases. Moreover, we evaluated the association between anaemia and nutrition problems. Methods: We prospectively evaluated immigrants younger than 18 years of age, from tropical or subtropical areas, who were referred on suspicion of or screening for imported diseases. Detailed medical records and physical and oral examinations were obtained. Blood count and biochemical measures of micronutrients and nutritional biomarkers were performed. We included microbiological methods for diagnosing imported infectious diseases according to the region of origin and clinical setting. Results: 373 minors were evaluated, including 250 (67.0%) from sub-Saharan Africa, 67 (18.0%) from North Africa and 56 (15.0%) from Latin America. The mean BMI of the subjects was 19.8±0.2. BMI increased by 0.02 for each month of stay in Spain. Nineteen patients (6.8%) had a nutritional risk of growth problems, and 50 (17.8%) were overweight. The time since arrival was longer in patients who were overweight (p<0.05). Twentyone minors (5.7%) had a haemoglobin count less than 11.5 g/dL. Children infected with intestinal helminthiasis had anaemia more frequently than uninfected patients, and children infected with intestinal protozoa had anaemia more frequently than uninfected patients (OR=2.7 I.C 1.1-7.0, p<0.05). Conclusions: Immigrant children in Spain have a low prevalence of growth problem, and being overweight is a frequent nutritional issue. A low level of ferritin is the most frequently detected nutritional problem and the main cause of anaemia. [ABSTRACT FROM AUTHOR]

Taking into consideration a behavioral approach a scale called the "Adolescent Food Habits Checklist" was developed in England to assess behaviors of adolescents with autonomous eating habits. To develop cross-cultural adaptation from English to Spanish of the "Adolescent Food Habits Checklist" to be applied in Venezuelan adolescents. A translation into Spanish by two independent translators was carried out. The obtained version was retranslated into English and evaluated by the original scale authors. Their recommendations were considered to confirm the content validity of the Spanish version. Last version was applied on 4 pilot tests to get a suitable scale with construct validity and internal consistency reliability. These parameters were reached in the fourth pilot test, which was developed with 200 adolescents between 15 and 19 years of age, of both male and female. An 18-item scale with a Cronbach alpha of 0.863 was obtained. Every item helped to keep a coefficient within 0.849 and 0.864 when they were removed. In addition, all of the items achieved a correlation item -- total higher than 0.3. The analysis of factors showed that most of the items are grouped into three factors that define the construct assessed with a weighing of each factor equal or over 0.4. The cumulative percentage of variance explained for these three factors was 50%. A cross-cultural adaptation of the scale with content validity, construct validity and high internal consistency reliability to be applied in Venezuelan adolescents was obtained. [ABSTRACT FROM AUTHOR]

Simple Summary: Obesity and overweight, considered the pandemic disease in the 21st century, is highly related to breast cancer. Leptin receptor (Ob-R) and its ligand leptin display an important role in driving this connection. Nowadays, translational cancer research is mainly focused on the identification of new biomarkers able to discriminate those patients deriving greater efficacy from a given therapy. In this regard, our study examines the role of Ob-R, namely, the correlation between Ob-R and pathological complete Response (pCR) in early breast cancer patients receiving neoadjuvant systemic therapy. Here, we decoded the correlation of Ob-R with certain clinical features such as breast cancer subtype, age, body mass index (BMI), menopausal status, and mammogram breast density. The study provides further support for the potential value of Ob-R for the first time as a possible role for predicting pCR. Moreover, we would like to highlight the importance of Ob-R as independent predictive factors for pCR in breast cancer patients. The primary aim of this retrospective study was to investigate the correlation between the immunohistochemical expression of Ob-R (leptin receptor) with pCR (pathological complete response) in early breast cancer patients receiving neoadjuvant systemic treatment (NST). A total of 100 women with breast cancer receiving NST (2017–2020) followed by surgical resection were retrospectively obtained. Demographic parameters and clinicopathological factors (e.g., treatment modalities, immunohistochemistry (IHC), and cancer subtype) were obtained from the patient's clinical records. In the analyzed breast cancer cohort, high expression of Ob-R was found in 52% of tumors and there was a significantly higher incidence in the HER2+ and TNBC subgroups. Overall, a significantly greater percentage of patients with Ob-R positive tumors achieved pCR compared with Ob-R negative patients (57.7% vs. 27.1%; p = 0.002). This result was observed in most breast cancer subtypes. In patients with HER2+ breast cancer, there was no difference in Ob-R expression in relation to the HR status. Ob-R cell positivity was significantly higher in younger breast cancer patients (p = 0.008), those who were premenopausal (p = 0.011), and in those with a BMI > 25 kg/m2 (p = 0.019). A significantly greater percentage of early breast cancer patients with Ob-R positive tumors achieved pCR compared with Ob-R negative patients. Furthermore, breast cancer patients with positive Ob-R expression were significantly younger than those with negative Ob-R expression. This association was not explained by differences in BMI between young and old patients. [ABSTRACT FROM AUTHOR]

Simple Summary: Considering the favorable overall safety profile of trastuzumab emtansine (T-DM1), the low expected rate of cardiotoxicity, and the synergistic effect of anthracyclines with Human Epidermal Growth Factor Receptor 2 (HER2)-targeting agents, it is hypothesized that T-DM1 may be safely combined with non-pegylated liposomal doxorubicin (NPLD). In the THELMA trial, the effect of adding NPLD to T-DM1 was evaluated with the aim of enhancing T-DM1 efficacy using an extensive cardiological assessment in trastuzumab- and taxane-pretreated patients with HER2-positive metastatic breast cancer. Despite an unlikely drug synergism, this combination was generally well tolerated without clinically relevant worsening of cardiac function. No relationship was identified between early predictors of heart failure and left ventricular ejection fraction changes. Thus, the combination of T-DM1 plus NPLD is safe, but this regimen does not seem to improve T-DM1 antitumor activity in this setting. The paper assesses the dose-limiting toxicities and the maximum tolerated dose (MTD) of trastuzumab emtansine (T-DM1) combined with non-pegylated liposomal doxorubicin (NPLD) in HER2-positive (HER2+) metastatic breast cancer (MBC). This single-arm, open-label, phase Ib trial (NCT02562378) enrolled anthracycline-naïve HER2+ MBC patients who had progressed on trastuzumab and taxanes. Patients received a maximum of 6 cycles of NPLD intravenously (IV) at various dose levels (45, 50, and 60 mg/m2) in the "3 plus 3" dose-escalation part. During expansion, they received 60 mg/m2 of NPLD every 3 weeks (Q3W) plus standard doses of T-DM1. The MTD was T-DM1 3.6 mg/kg plus NPLD 60 mg/m2 administered IV Q3W. No clinically relevant worsening of cardiac function was observed. Among all evaluable patients, the overall response rate was 40.0% (95%CI, 16.3–67.7) with a median duration of response of 6.9 months (95%CI, 4.8–9.1). Clinical benefit rate was 66.7% (95%CI, 38.4–88.2) and median progression-free survival was 7.2 months (95%CI, 4.5–9.6). No significant influence of NPLD on T-DM1 pharmacokinetics was observed. The addition of NPLD to T-DM1 is feasible but does not seem to improve the antitumor efficacy of T-DM1 in HER2+ MBC patients. [ABSTRACT FROM AUTHOR]

Background: Cystic echinococcosis (CE) is a well-known neglected parasitic disease. However, evidence supporting the four current treatment modalities is inadequate, and treatment options remain controversial. The aim of this work is to analyse the available data to answer clinical questions regarding medical treatment of CE.Methods: A thorough electronic search of the relevant literature without language restrictions was carried out using PubMed (Medline), Cochrane Central Register of Controlled Trials, BioMed, Database of Abstracts of Reviews of Effects, and Cochrane Plus databases up to February 1, 2017. All descriptive studies reporting an assessment of CE treatment and published in a peer-reviewed journal with available full-text were considered for a qualitative analysis. Randomized controlled trials were included in a quantitative meta-analysis. We used the standard methodological procedures established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.Results: We included 33 studies related to the pharmacological treatment of CE in humans. Of these, 22 studies with levels of evidence 2 to 4 were qualitatively analysed, and 11 randomized controlled trials were quantitatively analysed by meta-analysis.Conclusions: Treatment outcomes are better when surgery or PAIR (Puncture, Aspiration, Injection of protoscolicidal agent and Reaspiration) is combined with benzimidazole drugs given pre- and/or post-operation. Albendazole chemotherapy was found to be the primary pharmacological treatment to consider in the medical management of CE. Nevertheless, combined treatment with albendazole plus praziquantel resulted in higher scolicidal and anti-cyst activity and was more likely to result in cure or improvement relative to albendazole alone. [ABSTRACT FROM AUTHOR]